PUBLICATIONS Archives - Sagimet Biosciences

Graviton

0

PUBLICATIONS

September 6, 2019

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

Graviton

0

PUBLICATIONS

September 5, 2019

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Graviton

0

PUBLICATIONS

September 3, 2019

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

Graviton

0

PUBLICATIONS

February 13, 2018

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN (Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)

Graviton

0

PUBLICATIONS

October 23, 2017

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994).

Graviton

0

PUBLICATIONS

October 23, 2017

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Graviton

0

PUBLICATIONS

May 2, 2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Graviton

0

PUBLICATIONS

December 12, 2016

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel. (Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)

Graviton

0

PUBLICATIONS

November 11, 2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Graviton

0

PUBLICATIONS

November 8, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

PUBLICATIONS

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN (Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

Site Map

Contact Us